Cellyan Biotechnology Co., Ltd. - Form 6-K Filing

Cellyan Biotechnology Co., Ltd. held an extraordinary general meeting of shareholders on September 21, 2026. The shareholders approved a share consolidation with a ratio of 1-for-20 for both Class A and Class B ordinary shares. This consolidation will change the company's authorized share capital structure and par value per share. Fractional shares will not be issued, and shareholders will receive one consolidated share in lieu of fractional shares. The shareholders also approved amendments to the company's memorandum and articles of association to reflect this share consolidation. The Fifth Amended Memorandum and Articles of Association will replace the existing ones, effective upon the Share Consolidation's effective date. Directors and officers are authorized to make necessary filings with Nasdaq and the Cayman Registrar.